AgilVax Inc., announced today that Joseph Patti, PhD, President and Chief Executive Officer, will present an overview of the Company and provide an update on its portfolio of targeted antibody-based therapies addressing multiple cancers at the NYC Oncology Investor Conference on November 12, 2019 at 5:30 PM (ET). The conference is being held at the Perkins Coie law firm, 1155 6th Ave, New York City, NY.
AgilVax has demonstrated in preclinical in vivo models that antibodies to xCT were able to reduce primary tumor formation and the number of lung metastases. xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVax has multiple solutions to target cancer cells that overexpress xCT and when used in combination with existing therapies or alone have the potential to create a durable response in patients suffering from colorectal and other metastatic cancers.
About AgilVax
AgilVax is a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer. The Company has three development programs; an unmodified monoclonal antibody (mAb) targeting xCT, an antibody-drug conjugate targeting xCT, and AX09, a VLP-based xCT vaccine currently in cGMP production.
For more information, please visit http://www.agilvax.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191107005133/en/
Contacts:
